Redefining approaches in early lines of multiple myeloma
DARZALEX® (daratumumab) has proven efficacy and safety across multiple regimens and lines of therapy1
After ≥2 prior therapies
DARZALEX® + Pd*
(pomalidomide + dexamethasone)
*Prior therapies included lenalidomide and a proteasome inhibitor (PI).
†Prior therapies included a PI and an immunomodulatory agent, or patients were double-refractory to a PI and an immunomodulatory agent.